Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Fitzmaurice

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Trials|June 3, 2014
Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialNathan R Hill, Daniel Lasserson, Ben Thompson, et al.
Trials|December 12, 2022
Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialNathan R Hill, Daniel Lasserson, Ben Thompson, et al.
Health Technology Assessment (Winchester, England)|October 23, 2015
A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)Simon I Noble, Annmarie Nelson, David Fitzmaurice, et al.
Trials|April 22, 2022
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney diseaseHugh Gallagher, Jennifer Dumbleton, Tom Maishman, et al.
BMC Pulmonary Medicine|May 21, 2020
Supervised pulmonary hypertension exercise rehabilitation (SPHERe): study protocol for a multi-centre randomised controlled trialGordon McGregor, Julie Bruce, Stuart Ennis, et al.
Thorax|July 10, 2019
Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary careTosin Lambe, Peymane Adab, Rachel E Jordan, et al.
Pharmacogenetics and Genomics|September 16, 2009
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective studyAndrea L Jorgensen, Sameh Al-Zubiedi, Jieying Eunice Zhang, et al.
The Lancet. Respiratory Medicine|July 23, 2016
Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trialRachel E Jordan, Peymané Adab, Alice Sitch, et al.
Kardiologia Polska|December 20, 2014
[2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism], Stavros Konstantinides, Adam Torbicki, et al.
European Heart Journal|September 1, 2014
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolismStavros V Konstantinides, Adam Torbicki, Giancarlo Agnelli, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Trials|June 3, 2014
Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialNathan R Hill, Daniel Lasserson, Ben Thompson, et al.
Trials|December 12, 2022
Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialNathan R Hill, Daniel Lasserson, Ben Thompson, et al.
Health Technology Assessment (Winchester, England)|October 23, 2015
A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)Simon I Noble, Annmarie Nelson, David Fitzmaurice, et al.
Trials|April 22, 2022
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney diseaseHugh Gallagher, Jennifer Dumbleton, Tom Maishman, et al.
BMC Pulmonary Medicine|May 21, 2020
Supervised pulmonary hypertension exercise rehabilitation (SPHERe): study protocol for a multi-centre randomised controlled trialGordon McGregor, Julie Bruce, Stuart Ennis, et al.
Thorax|July 10, 2019
Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary careTosin Lambe, Peymane Adab, Rachel E Jordan, et al.
Pharmacogenetics and Genomics|September 16, 2009
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective studyAndrea L Jorgensen, Sameh Al-Zubiedi, Jieying Eunice Zhang, et al.
The Lancet. Respiratory Medicine|July 23, 2016
Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trialRachel E Jordan, Peymané Adab, Alice Sitch, et al.
Kardiologia Polska|December 20, 2014
[2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism], Stavros Konstantinides, Adam Torbicki, et al.
European Heart Journal|September 1, 2014
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolismStavros V Konstantinides, Adam Torbicki, Giancarlo Agnelli, et al.
Pageof 8